Clinical trial · Observational
The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt
NCT07509385CI-TRIAL-00107247not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study aimsTo measure the serum levels of IL-17 A and IL-10 in newly diagnosed patients with B-cell acute lymphoblastic leukemia (B-ALL). 2-To study the association between serum cytokine levels (IL-17 A and IL-10) and laboratory parameters, as well as the response to treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia, B-Cell | B Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- detection serum cytokine IL-17A and IL-10 level in Acute B-Lymphoblastic Leukemia
- timeFrame
- at baseline
Secondary outcomes (1)
- measure
- Study association between IL-17 A and IL-10 and clinicolaboratory data and patient outcome in Acute B Lymphoblastic leukemia patients
- timeFrame
- at baseline
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed acute B lymphoblastic leukemia patient Exclusion Criteria: * patients who received chemotherapy or immunotherapy * patients with other malignancies
References
Publications (5)
- BACKGROUNDZhao S, Wu D, Wu P, Wang Z, Huang J. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. PLoS One. 2015 Oct 6;10(10):e0139598. doi: 10.1371/journal.pone.0139598. eCollection 2015. PMID 26440936
- BACKGROUNDLee KY, Maggi M, Scotti C. Editorial: Biomarkers and therapeutic strategies in acute lymphoblastic leukemia. Front Cell Dev Biol. 2023 May 17;11:1211569. doi: 10.3389/fcell.2023.1211569. eCollection 2023. No abstract available. PMID 37266454
- BACKGROUNDIacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017 Mar 20;35(9):975-983. doi: 10.1200/JCO.2016.70.7836. Epub 2017 Feb 13. PMID 28297628
- BACKGROUNDOuyang W, O'Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019 Apr 16;50(4):871-891. doi: 10.1016/j.immuni.2019.03.020. PMID 30995504
- BACKGROUNDIshida H. [Clinical implication of IL-10 in patients with immune and inflammatory diseases]. Rinsho Byori. 1994 Aug;42(8):843-52. Japanese. PMID 7933621